Navigation Links
Arena Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
Date:2/23/2012

SAN DIEGO, Feb. 23, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Citi 2012 Global Health Care Conference on Wednesday, February 29, 2012, at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time) at the Waldorf=Astoria in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide a corporate overview.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena is seeking marketing approval of its most advanced drug candidate, which is intended for weight management and has been assigned by the US Food and Drug Administration (FDA) a new Prescription Drug User Fee Act (PDUFA) target date of June 27, 2012.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic indication of Arena's most advanced drug candidate, lorcaserin; seeking marketing approval of lorcaserin; the FDA's review of the lorcaserin NDA resubmission and the potential timing for the FDA to complete such review; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain, and the FDA may not complete its review of the lorcaserin NDA resubmission by the PDUFA date; the occurrence, timing and results of FDA advisory committee meetings relating to lorcaserin and other drug candidates; Arena's submission of a marketing authorization application for regulatory approval of lorcaserin may not occur, or be accepted, when anticipated, if at all; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to lorcaserin and Arena's other research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory review or approval; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Arena Pharmaceuticals, Inc.

 Robert E. Hoffman, Vice President, Finance and Chief Financial Officer 858.453.7200

  

 Investor Contact: Russo Partners, LLC

Media Contact: Russo Partners, LLCCindy McGee, Vice President

David Schull, President cindy.mcgee@russopartnersllc.com

david.schull@russopartnersllc.com619.213.6995

858.717.2310www.arenapharm.com

 


'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
2. Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Arena Submits Response to FDA Complete Response Letter for Lorcaserin
4. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
5. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
6. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
7. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
8. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
9. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
10. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
11. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 2017 Laboratory Markets Limited has completed a ... spectrometry in both clinical and research laboratory settings. This ... size of $6.8 billion and growing to $9.2 billion ... the use of mass spectrometry across more than 5,200 ... investigated growth in the use of mass spectrometry in ...
(Date:1/23/2017)... , Jan. 23, 2017 The Pharmacy ... the implementation of the planned 2020 accredited education ... PTCB originally announced in 2013 that the requirement ... a road map of program changes designed to ... in the pharmacy. "We have ...
(Date:1/23/2017)... , Jan. 23, 2017  Based on ... Frost & Sullivan recognizes Ansell, a global leader ... & Sullivan Company of the Year Award. Ansell,s ... and a wide global footprint have placed it ... hand protection market. The Company,s established product line ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... “Spiritual Vitamins: A Spiritual ... with God. “Spiritual Vitamins: A Spiritual Energy Booster” is the creation of published ... Mathai Yohannan’s new book engages the mind and spirit in a quest for ...
(Date:1/24/2017)... ... ... “The Octagon of Spiritual Balances”: a guide for the Christian seeking ... published author, Pastor Bernard J. Weathers, pastor of Word of Faith Ministries, in Colonia, ... and a master degree in theology. , ““The Octagon of Spiritual Balances” exposes the ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... scientific article suggests that autologous fat grafting—taking one’s own fat and ... naturally, without breast implants. , Cosmetic Surgeon and Medical Director of MilfordMD ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... Friday, January 20, with the bipartisan original co-sponsorship of nearly one-quarter of the ... 12. The National Association of Chain Drug Stores (NACDS) strongly backs the legislation. ...
(Date:1/24/2017)... Washington, D.C. (PRWEB) , ... January 23, 2017 ... ... today issued the following statement on the imposition of the Mexico City Policy, ... , The policy, enacted again today through Executive action, prohibits foreign non-governmental organizations ...
Breaking Medicine News(10 mins):